Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07680530 · ClinicalTrials.gov registry record
SpO2 Verification Study - Philips Nasal Alar With Nellcor OxiMax SpO2 Board (453564624031)
A clinical trial, sponsored by Philips Clinical & Medical Affairs Global.
- Recruiting
- Registry status
- 45
- Enrollment target
NCT07680530: Recruiting study, sponsored by Philips Clinical & Medical Affairs Global.
NCT07680530 is a clinical trial that is actively recruiting participants, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07680530 is actively recruiting participants, sponsored by Philips Clinical & Medical Affairs Global.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
Study Summary
The primary purpose of the clinical investigation is to verify the SpO2 accuracy of the Philips AlarX5 SpO2 sensor with Nellcor OxiMax SpO2 Board.
Primary Outcome
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
Interventions
- OTHER Evaluation of Oxygen Sensors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2026-06-24 |
What NCT07680530 shows while recruiting
NCT07680530 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Evaluation of Oxygen Sensors is the first listed.
NCT07680530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07680530 about?
NCT07680530 is a clinical study titled "SpO2 Verification Study - Philips Nasal Alar With Nellcor OxiMax SpO2 Board (453564624031)". The primary purpose of the clinical investigation is to verify the SpO2 accuracy of the Philips AlarX5 SpO2 sensor with Nellcor OxiMax SpO2 Board.
What is the current status of trial NCT07680530?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2026-05-28. Estimated completion is 2026-06-24.
What interventions are being tested in trial NCT07680530?
The interventions under investigation include: Evaluation of Oxygen Sensors (OTHER).
Who is sponsoring clinical trial NCT07680530?
This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI